CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial Heart failure with preserved ejection fraction: from mechanisms to therapies Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure

Review ArticleVolume 73, Issue 17, May 2019

JOURNAL:J Am Coll Cardiol. Article Link

Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review

M.G.D Buono, R Arena, BA Borlaug et al. Keywords: cardiorespiratory fitness; HFrEF; HFpEF; exercise capacity; comorbidities

ABSTRACT


Exercise intolerance is the cardinal symptom of heart failure (HF) and is of crucial relevance, because it is associated with a poor quality of life and increased mortality. While impaired cardiac reserve is considered to be central in HF, reduced exercise and functional capacity are the result of key patient characteristics and multisystem dysfunction, including aging, impaired pulmonary reserve, as well as peripheral and respiratory skeletal muscle dysfunction. We herein review the different modalities to quantify exercise intolerance, the pathophysiology of HF, and comorbid conditions as they lead to reductions in exercise and functional capacity, highlighting the fact that distinct causes may coexist and variably contribute to exercise intolerance in patients with HF.